Aeon Biopharma director Timothy Lynch buys $243,455 in stock
Aeon Biopharma's Director Timothy Lynch increased his stake in the company by acquiring 1,150,000 shares of Class A Common Stock on August 19, 2026. The purchase, worth approximately $243,455, was made at an average price of $0.2117 per share, with individual prices ranging from $0.1975 to $0.2164. Following the transaction, Lynch's direct beneficial ownership of AEON Biopharma stands at 6,500,000 shares.
This move comes as the stock trades near its 52-week low of $0.18, down 30% in the past week. Despite the recent decline, the stock is considered slightly undervalued by InvestingPro analysis, which offers 16 ProTips for further insights. Aeon Biopharma is currently advancing its biosimilar product, ABP-450, through the FDA's 351(k) pathway, with its analytical similarity strategy recently reviewed and approved.
The company has also received a Buy rating from H.C. Wainwright, albeit with its price target lowered from $5.00 to $1.20.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
